Abstract
Marine natural products (MNPs) provide an ample source of pharmacologically bioactive compounds with great chemical diversity and complexity. Peptide-derived MNPs are a class of compounds with diverse and interesting biological properties, such as antiinfective, anticancer, cytotoxic, and antiallodynic. Their biosynthetic production machinery from the ribosomal origin or non-ribosomal origin and the hybrid with other compounds confer these compounds remarkable diversity in terms of structural complexity as well as biological activity. The interest in these peptide compounds is their potential to produce valuable therapeutics and pharmaceuticals. Some of these peptides or their derivatives have reached the pharmaceutical market, while some are currently under clinical trials for developing new drugs. This review focuses on marine peptide-based compounds in advanced drug development for clinical use or pharmaceutical applications. The drug development process and clinical status of ribosomal peptides, non-ribosomal peptides and their hybrids, or the derivatives, are hereby described.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: IOP Conference Series: Materials Science and Engineering
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
